Implemed Olimpicc antimicrobial CVC catheter study gets funding from AmHS/Premier/SunHealth.
This article was originally published in The Gray Sheet
Executive SummaryIMPLEMED OLIMPICC ANTIMICROBIAL CENTRAL VENOUS CATHETER TRIALS are slated to begin during the next several weeks, the company says. Implemed received an investigational device exemption Dec. 8 to study the peripherally inserted catheter's antimicrobial performance, as well as its general safety and efficacy, the firm says.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.